Evidence map›Paper›PMID 34599475›Full record

ArticleCardiovascular toxicology2022

In Vivo and In Vitro Cardioprotective Effect of Gossypin Against Isoproterenol-Induced Myocardial Infarction Injury.

Irfan Cinar, Muhammed Yayla, Taha Tavaci, Erdem Toktay, Rustem Anil Ugan, Pınar Bayram, Hamza Halici

Abstract read
PubMed Publisher
In one paragraph

Article in Cardiovascular toxicology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 37 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Unraveling the Therapeutic Potential ofCurrent pharmaceutical design · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. A New Target in Inflammatory Diseases: Lycopene.The Eurasian journal of medicine · 2022
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Irfan CinarDepartment of Pharmacology, Faculty of Medicine, Kastamonu University, 3700, Kastamonu, Turkey. atairfan.nar@gmail.com.ORCID 0000-0002-9826-2556
Muhammed YaylaFaculty of Medicine, Department of Pharmacology, Kafkas University, Kars, Turkey.
Taha TavaciFaculty of Medicine, Department of Pharmacology, Atatürk University, Erzurum, Turkey.
Erdem ToktayFaculty of Medicine, Department of Histology and Embriology, Kafkas University, Kars, Turkey.
Rustem Anil UganFaculty of Pharmacy, Department of Pharmacology, Atatürk University, Erzurum, Turkey.
Pınar BayramFaculty of Medicine, Department of Histology and Embriology, Kafkas University, Kars, Turkey.
Hamza HaliciFaculty of Medicine, Department of Pharmacology, Atatürk University, Erzurum, Turkey.
Atatürk University · TRKafkas University · TRKastamonu University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of the study was to examine the protective effects and possible mechanism of gossypin against isoproterenol (ISO)-mediated myocardial damage in vivo and H9c2 cell damage in vitro. H9c2 cells were categorized into five groups. Viability was evaluated with MTT and LDH release in H9c2 cells. Apoptotic parameter analysis was performed with cytochrome c (Cyt-c), caspase-3 (CASP-3), and BCL2/Bax mRNA expression levels. In vivo, gossypin was administered orally to mice at doses of 5, 10, and 20 mg/kg for 7 days. ISO groups were injected with isoproterenol (150 mg/kg) subcutaneously (on 8th and 9th) for 2 days. Afterward, lactate dehydrogenase (LDH), creatine kinase-MB (CK-MB) levels and Troponin-I (Tn-I) amount from their serum, oxidative stress parameters superoxide dismutase (SOD) activity, glutathione (GSH) and malondialdehyde (MDA) levels, and tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), interleukin-1β (IL-1 β), and NF-kB mRNA expression levels with inflammatory markers from heart tissue were evaluated. In addition, IL-1B, BCL-2, and cas-3 immunohistochemical staining was performed from heart tissue and TNF-a level was measured by ELISA method. Administration of Gossypin protected the cells by dose-dependent, eliminating the reduced cell viability and increased LDH release of ISO in H9c2 cells. In mice serum analyses, increased LDH, CK-MB levels, and Tn-I levels were normalized by gossypin. ISO administration in heart tissue is regulated by gossypin with increased SOD activity, GSH amount, TNF-α, IL-6, IL-1β, and NF-kB mRNA expression levels and decreased MDA amount. Overall, the present results demonstrated that gossypin has a potential cardioprotective treatment for ischemic heart disease on in vivo and in vitro.

Indexed as

AnimalsAnti-Inflammatory AgentsAntioxidantsApoptosisApoptosis Regulatory ProteinsCardiotoxicityCell LineCytokinesDisease Models, AnimalFlavonoidsInflammation MediatorsIsoproterenolMaleMiceMice, Inbred BALB CMyocardial InfarctionAnti-Inflammatory AgentsAntioxidantsApoptosis Regulatory ProteinsCytokinesFlavonoidsgossypinInflammation MediatorsIsoproterenolAntioxidantCardioprotectionGossypinIsoproterenolMyocardial infarction

Identifiers

PMID34599475
OpenAlexW3202875065

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.